Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
RNA interference (RNAi) is a universal and evolutionarily conserved phenomenon of post-transcriptional gene silencing by means of sequence-specific mRNA degradation, triggered by small double-stranded RNAs. Because this mechanism can be efficiently induced in vivo by expressing target-complementary short hairpin RNA (shRNA) from non-viral and viral vectors, RNAi is attractive for functional genomics and human therapeutics. Here we systematically investigate the long-term effects of sustained high-level shRNA expression in livers of adult mice. Robust shRNA expression in all the hepatocytes after intravenous infusion was achieved with an optimized shRNA delivery vector based on duplex-DNA-containing adeno-associated virus type 8 (AAV8). An evaluation of 49 distinct AAV/shRNA vectors, unique in length and sequence and directed against six targets, showed that 36 resulted in dose-dependent liver injury, with 23 ultimately causing death. Morbidity was associated with the downregulation of liver-derived microRNAs (miRNAs), indicating possible competition of the latter with shRNAs for limiting cellular factors required for the processing of various small RNAs. In vitro and in vivo shRNA transfection studies implied that one such factor, shared by the shRNA/miRNA pathways and readily saturated, is the nuclear karyopherin exportin-5. Our findings have fundamental consequences for future RNAi-based strategies in animals and humans, because controlling intracellular shRNA expression le…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cellular toxicity can, for example, be observed in rAAV shRNA overexpression studies in which ubiquitous promoters were used that caused saturation of cellular miRNA pathways [88].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“However, the relatively large size, the requirement that the transcript starts with a G or A, the sometimes too active transcription, and the sensitivity to specific cellular profiles make the human U6 promoter a less versatile promoter [88,131,132].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“Consistent with this possibility, when multiple miRNAs are packaged within a single construct, they may compete for processing by the cellular miRNA biogenesis machinery, leading to reduced efficiency in individual miRNA maturation and function 44,45 .”
From rAAV-mediated Multi-miRNA Delivery Targeting MAPK Pathway Suppresses Laser-induced Choroidal Neovascularization in Mice (2026) · cites this paper as [44]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs
Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003) · Genes & Development · doi:10.1101/gad.1158803 · Cited by 3,010
Nuclear Export of MicroRNA Precursors
Lund, E., Güttinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004) · Science · doi:10.1126/science.1090599 · Cited by 2,714
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., & Sarnow, P. (2005) · Science · doi:10.1126/science.1113329 · Cited by 2,521
Self-citationExportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs
BOHNSACK, M. T., CZAPLINSKI, K., & GÖRLICH, D. (2004) · RNA · doi:10.1261/rna.5167604 · Cited by 1,433
Cited by
Items 901–1,000 of 1,001
Chang, Z., Babiuk, L. A., & Hu, J. (2007) · BioDrugs · doi:10.2165/00063030-200721010-00002 · Cited by 19
Haldrup, S. H., Fabian-Jessing, B. K., Jakobsen, T. S., Lindholm, A. B., Adsersen, R. L., Aagaard, L., Bek, T., Askou, A. L., & Corydon, T. J. (2024) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2024.101242 · Cited by 18
“20 However, these challenges may be circumvented by developments in RNAi technology.”
BackgroundFSHD Therapeutic Strategies: What Will It Take to Get to Clinic?
Himeda, C. L., & Jones, P. L. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060865 · Cited by 21
“siRNAs, shRNAs, and miRNAs depend on RNAi, thus competing with normal substrates of the RISC complex and sometimes oversaturating the capabilities of this pathway [74].”
BackgroundRahdan, F., Saberi, A., Saraygord‐Afshari, N., Hadizadeh, M., Arjmand, T. F., Ghanbari, E., Dianat‐Moghadam, H., & Alizadeh, E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39489 · Cited by 18
“Another approach is to use the administration of miRNA expression vectors, which transfer DNA encoding the target miRNA and provide high levels of miRNA required by the cell. miRNA expression vectors are designed to be locally introduced into the target tissues [187].”
BackgroundshRNA Off-Target Effects In Vivo: Impaired Endogenous siRNA Expression and Spermatogenic Defects
Song, H.-W., Bettegowda, A., Oliver, D., Yan, W., Phan, M. H., de Rooij, D. G., Corbett, M. A., & Wilkinson, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118549 · Cited by 20
“, EXPORTIN5 and/or RNA-induced silencing complexes) away from endogenous miRNA precursors and thereby impairs miRNA processing [41–43].”
BackgroundWang, Z., Feng, C., Zhao, H., Ren, X., Peng, S., & Zuo, Z. (2015) · Theranostics · doi:10.7150/thno.10441 · Cited by 19
“These designs allow robust shRNA production that is difficult to regulate and can saturate endogenous microRNA processing machinery to induce cell toxicity [3].”
BackgroundTargeting neurological disease with RNAi
Lingor, P., & Bähr, M. (2007) · Molecular BioSystems · doi:10.1039/b701169e · Cited by 21
Using Lentiviral Vectors as Delivery Vehicles for Gene Therapy
Dissen, G. A., McBride, J. L., Lomniczi, A., Matagne, V., Dorfman, M. D., Neff, T. L., Galimi, F., & Ojeda, S. R. (2011) · Neuromethods · doi:10.1007/978-1-61779-533-6_4 · Cited by 19
Noncoding RNA for Cancer Gene Therapy
Zhong, X., Zhang, D., Xiong, M., & Zhang, L. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42934-2_4 · Cited by 19
“2009), and saturation of endogenous RNAi pathway components (Khan et al. 2009; Grimm et al. 2006).”
BackgroundAAV8-mediated gene transfer of microRNA-132 improves beta cell function in mice fed a high-fat diet
Mulder, N. L., Havinga, R., Kluiver, J. L., Groen, A. K., & Kruit, J. K. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0287 · Cited by 18
Kaadt, E., Alsing, S., Cecchi, C. R., Damgaard, C. K., Corydon, T. J., & Aagaard, L. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.013 · Cited by 18
Optimized Protocol for Accurate Titration of Adeno-Associated Virus Vectors
Suoranta, T., Laham-Karam, N., & Ylä‐Herttuala, S. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.318 · Cited by 21
“2,3 In extreme cases, this disparity can be the difference between therapeutic efficacy and toxicity, as was observed in response to in vivo short hairpin RNA delivery in mice, 4 highlighting how crucial it is to minimize such differences.”
Going Off-Grid: Continuous Implicit Neural Representations for 3D Vascular Modeling
Alblas, D., Brüne, C., Yeung, K. K., & Wolterink, J. M. (2022) · Lecture notes in computer science · doi:10.1007/978-3-031-23443-9_8 · Cited by 26
Chapter 5 MicroRNA-Mediated Gene Silencing
Pager, C. T., Wehner, K. A., Fuchs, G., & Sarnow, P. (2009) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(09)90005-9 · Cited by 21
Increased in vivo inhibition of gene expression by combining RNA interference and U1 inhibition
Blázquez, L., Gonzalez-Rojas, S. J., Abad, A., Razquin, N., Abad, X., & Fortes, P. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr956 · Cited by 18
Depletion of newly synthesized Argonaute1 impairs the RNAi response in Trypanosoma brucei
Shi, H., Tschudi, C., & Ullu, E. (2007) · RNA · doi:10.1261/rna.474707 · Cited by 19
“More recently, overexpression of small hairpin RNAs (shRNAs) in mice resulted in toxicity (Grimm et al. 2006), suggesting that the endogenous miRNA-mediated pathway may be deregulated by the expression of large amounts of shRNAs.”
BackgroundTiash, S., & Chowdhury, E. H. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1525388 · Cited by 19
Combination of RNA interference and U1 inhibition leads to increased inhibition of gene expression
Abad, X., Razquin, N., Abad, A., & Fortes, P. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq299 · Cited by 18
“The three major reasons for this are: (i) some siRNA molecules are sensed by the cell leading to activation of the interferon response (8,9); (ii) overexpression of siRNAs can saturate the cellular silencing machinery which is required to control the expression of many genes involved in essential cellular processes (1…”
BackgroundVaessen, S. F. C., Veldman, R. J., Comijn, E. M., Snapper, J., Sierts, J. A., van den Oever, K., Beattie, S. G., Twisk, J., & Kuivenhoven, J. A. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1344 · Cited by 19
“two different self-complementary vectors, containing either the liver-specific promoter LP1 [16] or the liverspecific TTR promoter [15], could induce higher hApoA-I”
InfluentialProgress in the Therapeutic Applications of siRNAs Against HIV-1
Martínez, M. Á. (2008) · Methods in molecular biology · doi:10.1007/978-1-60327-547-7_17 · Cited by 19
“A previous study in which mice were treated with high doses of a viral vector expressing shRNAs that resulted in high copy numbers per cell led to fatality due to oversaturation of the mi/siRNA pathways (65) .”
BackgroundCalcium Phosphate and Calcium Phosphosilicate Mediated Drug Delivery and Imaging
Pinto, O. A., Tabaković, A., Goff, T. M., Liu, Y., & Adair, J. H. (2011) · Fundamental biomedical technologies · doi:10.1007/978-94-007-1248-5_23 · Cited by 17
Pucci, P., Lee, L. C., Han, M., Matthews, J. D., Jahangiri, L., Schlederer, M., Manners, E., Sorby-Adams, A. J., Kaggie, J. D., Trigg, R. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47771-x · Cited by 18
Toward a Durable Treatment of HIV-1 Infection Using RNA Interference
Eekels, J. J. M., & Berkhout, B. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-415795-8.00001-5 · Cited by 22
RNA Interference in Mammalian Cell Systems
Lochmatter, D., & Mullis, P.-E. (2011) · Hormone Research in Paediatrics · doi:10.1159/000322817 · Cited by 20
Inducible RNAi system and its application in novel therapeutics
Liao, Y., & Tang, L. (2015) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2014.1003030 · Cited by 20
“Other limitations such as competition with endogenous RNAs and off targets which are well known for shRNA application also block the application of inducible RNAi (Grimm et al., 2006; Johnson et al., 2005; Lim et al., 2005; Lin et al., 2005).”
BackgroundSelection of RNAi-based inhibitors for anti-HIV gene therapy
Knoepfel, S. A., Centlivre, M., Liu, Y. P., Boutimah, F., & Berkhout, B. (2012) · World Journal of Virology · doi:10.5501/wjv.v1.i3.79 · Cited by 17
A Versatile RNA Vector for Delivery of Coding and Noncoding RNAs
Schmid, S., Zony, L. C., & tenOever, B. R. (2013) · Journal of Virology · doi:10.1128/jvi.03267-13 · Cited by 17
Computational Models of HIV-1 Resistance to Gene Therapy Elucidate Therapy Design Principles
Aviran, S., Shah, P. S., Schaffer, D. V., & Arkin, A. P. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000883 · Cited by 18
“An example of the latter case is a combination of RNAi targets, which is constrained by a maximum tolerable level of siRNA molecules so as to avoid toxicity [67] and”
BackgroundTrang, P., Weidhaas, J. B., & Slack, F. J. (2016) · Springer eBooks · doi:10.1007/978-1-59745-458-2_17 · Cited by 22
Fakhiri, J., Nickl, M., & Grimm, D. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9170-9_8 · Cited by 18
Self-citationKaban, K., Şalva, E., & Akbuğa, J. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3116 · Cited by 18
“In addition, overdose miRNA administration may be toxic as a result of saturation of the endogenous miRNA pathway.(41,42) When planning replacement therapy, the aim should be to reach the normal levels found in noncancerous cells.”
BackgroundVEGFA-targeting miR-agshRNAs combine efficacy with specificity and safety for retinal gene therapy
Alsing, S., Doktor, T. K., Askou, A. L., Jensen, E. G., Ahmadov, U., Kristensen, L. S., Andresen, B. S., Aagaard, L., & Corydon, T. J. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.02.019 · Cited by 19
Vulf, M. A., Хлусов, И. А., Yurova, K. A., Тодосенко, Н. М., Komar, A., Kozlov, I. G., Malashchenko, V. V., Shunkina, D., Хазиахматова, О. Г., & Litvinova, L. S. (2022) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1403017 · Cited by 19
Intraperitoneal AAV9-shRNA inhibits target expression in neonatal skeletal and cardiac muscles
Mayra, A., Tomimitsu, H., Kubodera, T., Kobayashi, M., Piao, W., Sunaga, F., Hirai, Y., Shimada, T., Mizusawa, H., & Yokota, T. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.01.009 · Cited by 17
Antisense Gene Silencing: Therapy for Neurodegenerative Disorders?
Nielsen, T. T., & Nielsen, J. E. (2013) · Genes · doi:10.3390/genes4030457 · Cited by 19
Seyhan, A. A. (2015) · Molecular BioSystems · doi:10.1039/c5mb00506j · Cited by 17
RNA interference-based technology: what role in animal agriculture?
Bradford, B. J., Cooper, C. A., Tizard, M. L., Doran, T. J., & Hinton, T. M. (2016) · Animal Production Science · doi:10.1071/an15437 · Cited by 17
“Initial development of genetically engineered mice expressing shRNA resulted in severe medical problems due to overexpression of the RNAi molecule, which led to dysfunction in the processing of the required endogenous miRNA (Grimm et al. 2006).”
BackgroundBiological Antivirals for Treatment of Adenovirus Infections
Schaar, K., Röger, C., Pozzuto, T., Kurreck, J., Pinkert, S., & Fechner, H. (2015) · Antiviral Therapy · doi:10.3851/imp3047 · Cited by 17
“However, shRNAs may lead to hepatocytotoxicity in some cases by saturating the cellular RNAi pathway [51].”
BackgroundLam, S., Chen, H., Chen, C. K., Min, N., & Chu, J. J. H. (2015) · Scientific Reports · doi:10.1038/srep12727 · Cited by 17
“However, treatment-induced toxicity and the high susceptibility of siRNA to intracellular degradation posed as limitations in furthering the development of shRNA for pre-clinical applications 57, 58 .”
BackgroundState of art and limitations in genetic engineering to induce stable chondrogenic phenotype
Graceffa, V., Vinatier, C. S., Guicheux, J., Evans, C. H., Stoddart, M. J., Alini, M., & Zeugolis, D. I. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.07.004 · Cited by 18
The application of RNAi-based treatments for inflammatory bowel disease
Olesen, M. T. J., Ballarín-González, B., & Howard, K. A. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0156-9 · Cited by 17
Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors
Lebedev, T. D., Spirin, P., & Prassolov, V. (2013) · Acta Naturae · doi:10.32607/20758251-2013-5-2-7-18 · Cited by 17
Croft, L. V., Fisher, M., Barbhuiya, T. K., El‐Kamand, S., Beard, S., Rajapakse, A., Gamsjaeger, R., Cubeddu, L., Bolderson, E., O'Byrne, K. J., et al. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0056 · Cited by 16
“65,66 Both intracellular protein binding and miRNA machinery competition are possible mechanisms that drive cytotoxicity in the hairpin-forming SSOs within our dataset.”
Conditional RNA interference in mammalian cells via RNA transactivation
Zhou, Y., Sheng, P., Li, J., Li, Y., Xie, M., & Green, A. A. (2024) · Nature Communications · doi:10.1038/s41467-024-50600-w · Cited by 16
“By ensuring that RNAi is only activated when desired, they can help avoid over-burdening the endogenous miRNA biogenesis machinery 42 and thus minimize their impact on host cell function.”
Jan, S. A., Debnath, A., Singh, R. K., Tyagi, P. K., Singh, S. K., & Singh, A. K. (2025) · Current Gene Therapy · doi:10.2174/0115665232357160250123113148 · Cited by 19
Crowther, C. E., Maepa, M. B., Ely, A., & Arbuthnot, P. B. (2013) · Antiviral Therapy · doi:10.3851/imp2713 · Cited by 16
“We observed that HD Ad-mediated transduction of hepatocytes with similar cassettes was well tolerated and the dramatic toxic effects reported by Grimm and colleagues [47] could not be discerned.”
BackgroundProspects for nucleic acid-based therapeutics against hepatitis C virus
Lee, C. H., Kim, J. H., & Lee, S. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i47.8949 · Cited by 18
Stacking up CRISPR against RNA i for therapeutic gene inhibition
Haussecker, D. (2016) · FEBS Journal · doi:10.1111/febs.13742 · Cited by 18
Goguen, R. P., Corpo, O. D., Malard, C. M. G., Daher, A., Alpuche‐Lazcano, S. P., Chen, M. J., Scarborough, R. J., & Gatignol, A. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.12.022 · Cited by 17
“48 Twostudiesshowed that adverse effects of shRNAs expressed from the U6 promoter could bepreventedbyusingtheH1promoterinstead.”
Hinton, T. M., Wise, T. G., Cottee, P. A., & Doran, T. J. (2008) · PubMed Central · Cited by 18
A potential treatment for pandemic influenza using siRNAs targeting conserved regions of influenza A
McSwiggen, J. A., & Seth, S. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.3.299 · Cited by 17
“A 2006 paper by Kay and colleagues has reported an extreme case of this occurring in mice [88] , but a recent paper by John et al.”
BackgroundU6 promoter-driven siRNA injection has nonspecific effects in zebrafish
Wang, L., Zhou, J., Yao, J., Lu, D., Qiao, X., & Jia, W. W.-G. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.065 · Cited by 16
Use of RNA interference to minimize ischemia reperfusion injury
Zhang, Z., Min, W., & Jevnikar, A. M. (2011) · Transplantation Reviews · doi:10.1016/j.trre.2011.03.001 · Cited by 16
“However, oversaturation using very high doses of viral shRNA administration can lead to tissue damage and toxicity [67].”
BackgroundArtificial mirtron-mediated gene knockdown: Functional DMPK silencing in mammalian cells
Seow, Y., Sibley, C. R., & Wood, M. J. A. (2012) · RNA · doi:10.1261/rna.030601.111 · Cited by 17
Mihaila, R., Ruhela, D., Galinski, B., Card, A., Cancilla, M. T., Shadel, T. R., Kang, J., Tep, S., Wei, J., Haas, R. M., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.03.004 · Cited by 16
“16 June 2019 ities due to competition between shRNAs for the RNAi machinery.(28) We were therefore interested in trying to mechanistically understand the factors that govern siRNA competition and propose ways to alleviate competition in vivo.”
BackgroundRiboregulators in kidney development and function
Karolina, D. S., Wintour, E. M., Bertram, J. F., & Jeyaseelan, K. (2010) · Biochimie · doi:10.1016/j.biochi.2009.12.008 · Cited by 15
Blahetek, G., Mayer, C. A., Zuber, J. A., Lenter, M., & Strobel, B. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101280 · Cited by 16
“MiRNAs are a class of short (21 – 23 nt), non-coding RNAs that regulate gene expression post-transcriptionally by base pairing to complementary binding sites that are typically located within the 3 0 UTR of mRNAs.”
BackgroundA Simple and Robust Vector-Based shRNA Expression System Used for RNA Interference
Wang, X., Li, Y., Huang, H., Zhang, X., Pei-wen, X., Hu, W. M., Li, D.-D., & Wang, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056110 · Cited by 15
“First, we employed the H1 RNA polymerase III promoter instead of U6 whose toxicity has been previously identified [13].”
MethodApplications of RNA interference-based gene silencing in animal agriculture
Long, C. R., Tessanne, K. J., & Golding, M. C. (2009) · Reproduction Fertility and Development · doi:10.1071/rd09211 · Cited by 16
“First, overexpression of shRNAs in mammalian cells sometimes overloads the endogenous RNAi pathway, diminishing the ability of RISC to perform its ‘normal’ function (Grimm et al. 2006).”
BackgroundWang, S., Chen, C., Zhou, Y., Chi, X., Zhang, J., & Chen, J. (2016) · Scientific Reports · doi:10.1038/srep23746 · Cited by 15
Gene therapeutic approaches to inhibit hepatitis B virus replication
Gebbing, M., Bergmann, T., Schulz, E., & Ehrhardt, A. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v7.i2.150 · Cited by 17
Rapid Generation of Long Noncoding RNA Knockout Mice Using CRISPR/Cas9 Technology
Hansmeier, N. R., Widdershooven, P. J. M., Khani, S., & Kornfeld, J. (2019) · Non-Coding RNA · doi:10.3390/ncrna5010012 · Cited by 15
“To understand the molecular contribution of lncRNAs to health and disease, for instance by investigating the phenotypic consequences of lncRNA alteration in vivo, the field needs simple, robust, cheap and standardized approaches to disrupt lncRNA function and bypass some confounding factors of performing RNA interfere…”
BackgroundRNA interference in glial cells for nerve injury treatment
Lin, J., Jo, S. B., Kim, T.-H., Kim, H., & Chew, S. Y. (2020) · Journal of Tissue Engineering · doi:10.1177/2041731420939224 · Cited by 15
Potential mechanisms for cell-based gene therapy to treat HIV/AIDS
Herrera-Carrillo, E., & Berkhout, B. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.980236 · Cited by 16
“The expression level of shRNAs should not be too high to avoid cellular toxicity due to saturation of the cellular RNAi/ miRNA pathway [124].”
BackgroundKolniak, T. A., & Sullivan, J. M. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.01.004 · Cited by 15
“For example, RNAi technology has been associated with fatalities in mice apparently due not to activation of the RNA-dependent protein kinase/interferon pathway or the presence of a shRNA target, but rather as a result of competition of expressed shRNAs with naturally expressed microRNAs (miRNAs) for intracellular pro…”
BackgroundCurrent Progress and Challenges in HIV Gene Therapy
Chung, J., Rossi, J. J., & Jung, U. (2011) · Future Virology · doi:10.2217/fvl.11.113 · Cited by 16
“Commonly used Pol III promoters include the human H1 and U6 promoters, for which concerns have been raised about their activity being too high for safe application [85].”
BackgroundBattistella, M., & Marsden, P. A. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.8 · Cited by 15
“argued that the export of shRNA and pre-miRNA from the nucleus used a common mediator, namely, exportin-5.(84) They provided compelling evidence that cells transfected with”
BackgroundInfluentialShariat, N. W., Ryther, R. C. C., Phillips, J. A., Robinson, I. C. A. F., & Patton, J. G. (2007) · Endocrinology · doi:10.1210/en.2007-1360 · Cited by 15
“Although overexpression of shRNAs can lead to toxicity and lethality due to oversaturation of the endogenous micro-RNA pathway or due to possible off-target effects (12, 13), the presence of the shRNA-17.”
BackgroundWongsrikeao, P., Sutou, S., 國司, 美., Dong, Y. J., Bai, X., & Otoi, T. (2011) · Prion · doi:10.4161/pri.5.1.14075 · Cited by 19
“Indeed, a U6 promoter was reported to be fatally hazardous in mouse experiments.(20) Therefore, we compared the utility of type II (tRNA) and type Figure 1.”
BackgroundSystemic delivery of therapeutics to neuronal tissues: a barrier modulation approach
Campbell, M., Ozaki, E., & Humphries, P. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.490554 · Cited by 15
Introduction to Viral Vectors and Other Delivery Methods for Gene Therapy of the Nervous System
Manfredsson, F. P. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3271-9_1 · Cited by 17
Polymers in the Delivery of siRNA for the Treatment of Virus Infections
Reynolds, N. P., Dearnley, M., & Hinton, T. M. (2017) · Topics in Current Chemistry · doi:10.1007/s41061-017-0127-6 · Cited by 15
“May result in excess RNAi molecule expression, leading to saturation of the natural miRNA pathways and resulting in severe toxicities [46]”
BackgroundNovel AgoshRNA molecules for silencing of the CCR5 co-receptor for HIV-1 infection
Herrera-Carrillo, E., & Berkhout, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177935 · Cited by 15
RNA interference to enhance radiation therapy: Targeting the DNA damage response
Ratnayake, G., Bain, A. L., Fletcher, N. L., Howard, C. B., Khanna, K. K., & Thurecht, K. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.011 · Cited by 16
Protein-based vehicles for biomimetic RNAi delivery
Pottash, A. E., Kuffner, C. J., Noonan-Shueh, M., & Jay, S. M. (2019) · Journal of Biological Engineering · doi:10.1186/s13036-018-0130-7 · Cited by 16
“expression of exogenous shRNA in the liver consistently led to fatality in mice due to saturation of RNAi machinery [89].”
BackgroundGene Therapy Strategies to Block HIV-1 Replication by RNA Interference
Herrera-Carrillo, E., & Berkhout, B. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-2432-5_4 · Cited by 22
Off and back-on again: a tumor suppressor’s tale
Acosta, J., Wang, W., & Feldser, D. M. (2018) · Oncogene · doi:10.1038/s41388-018-0186-3 · Cited by 15
“These heterologous transgenes therefore outcompete endogenous miRNAs for access to the processing components of the RNA interference pathway and indirectly lead to the rise in transcript levels that are normally suppressed by endogenous miRNAs [47].”
BackgroundSmall RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions
Cronin, J. M., & Yu, A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1720361 · Cited by 17
Lin, C., Yang, Y.-S., Ma, H., Chen, Z., Chen, D., John, A. A., Xie, J., Gao, G., & Shim, J. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.036 · Cited by 14
“65,66 Therefore, we used an AAV-compatible SHN3 silencer ( amiR-SHN3, hs-amiR-SHN3, hs-amiR-hSHN3 ).”
AAV-mediated in vivo knockdown of luciferase using combinatorial RNAi and U1i
Koornneef, A., van Logtenstein, R., Timmermans, E., Pisas, L., Blits, B., Abad, X., Fortes, P., Petry, H., Konstantinova, P. S., & Ritsema, T. (2011) · Gene Therapy · doi:10.1038/gt.2011.41 · Cited by 14
Constitutive Expression of Short Hairpin RNA in Vivo Triggers Buildup of Mature Hairpin Molecules
Ahn, M., Witting, S. R., Ruiz, R., Saxena, R., & Morral, N. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.234 · Cited by 15
“…it has been shown that cells have a limited capacity to process shRNA, and that oversaturation of the exportin-5 pathway (necessary to transport shRNA to the cytoplasm) by high-level shRNA expression results in downregulation of endogenous micro-RNAs, inducing cell death (Grimm et al. , 2006).”
InfluentialInducible and reversible regulation of endogenous gene in mouse
Sun, R., Zhao, K., Shen, R., Cai, L., Yang, X., Kuang, Y., Mao, J., Huang, F., Wang, Z., & Fei, J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks738 · Cited by 14
Jiang, X., Yu, H., Teo, C. R., Tan, G. S. X., Goh, S. C., Patel, P. S., Chua, Y. K., Hameed, N. B. S., Bertoletti, A., & Patzel, V. (2016) · Molecular Therapy · doi:10.1038/mt.2016.138 · Cited by 14
Danielsen, M. B., & Wengel, J. (2021) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.17.125 · Cited by 15
Bauer, A., Puglisi, M., Nagl, D., Schick, J., Werner, T. A., Klingl, A., Andari, J. E., Hornung, V., Kessler, H., Götz, M., et al. (2022) · Advanced Science · doi:10.1002/advs.202104979 · Cited by 21
Self-citationUnlocking the potential of RNA-based therapeutics in the lung: current status and future directions
Man, H. S. J., Moosa, V. A., Singh, A. N., Wu, L., Granton, J. T., Juvet, S., Hoang, C. D., & de Perrot, M. E. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1281538 · Cited by 15
“Therefore, methods to assess the effects of different doses of RNAs on direct and indirect gene regulation to avoid RISC saturation can be employed (Grimm et al., 2006).”
BackgroundMethodInduction of Somatic Cell Reprogramming Using the MicroRNA miR-302
Kelley, K. M. M., & Lin, S.-L. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-398459-3.00004-6 · Cited by 14
Wagner, A., Röhrs, V., Kedzierski, R., Fechner, H., & Kurreck, J. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.095 · Cited by 15
“Toxicity studies clearly demonstrated that the accurate determination of AAV vector titers is essential for their successful application for RNAi and gene therapy (Grimm et al. , 2006).”
InfluentialReview article: RNA interference – potential therapeutic applications for the gastroenterologist
Pellish, R. S., NASIR, A., Ramratnam, B., & Moss, S. F. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03634.x · Cited by 14
siRNA: novel therapeutics from functional genomics
Joshi, B. H., & Pachchigar, K. P. (2014) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2014.921495 · Cited by 15
“Furthermore as synthetic siRNA enter the RNAi pathway in later stage, they are less prone to degradation by endogenous miRNAs mediated regulation (Grimm et al., 2006).”
BackgroundLavender, H., Brady, K., Burden, F., Delpuech-Adams, O. E., Denise, H., Palmer, A., Perkins, H., Savic, B., Scott, S., Smith‐Burchnell, C., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05357-11 · Cited by 14
Progress towards Therapeutic Application of RNA Interference for HIV Infection
Singh, S. K., & Gaur, R. K. (2009) · BioDrugs · doi:10.2165/11317120-000000000-00000 · Cited by 16
Small Interfering RNA for Effective Cancer Therapies
Wang, X., Chen, Y., Ren, J., & Qu, X.-H. (2011) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955711794519528 · Cited by 14
Choi, S. H., Shin, H. W., Park, J. Y., Yoo, J. Y., Kim, D. Y., Ro, W. S., Yun, C., & Han, K. (2010) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2010.16.3.280 · Cited by 14
“Actually, efficient transfer of RNAi into the cell by the virus vectors such as, retrovirus and adenovirus have already been confirmed.(26,27) Also, one of the weak points of siRNA is that the in vivo duration time is short, 28 but recently it is reported that the short duration time can be solved by using the virus v…”
BackgroundThe anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA
Lisowski, L., Elazar, M., Chu, K. C., Glenn, J. S., & Kay, M. A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt068 · Cited by 14
Self-citationStrategies in Designing Multigene Expression Units to Downregulate HIV-1
Zhang, J., & Rossi, J. J. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-588-0_8 · Cited by 14
Gene, Stem Cell, and Alternative Therapies for SCA 1
Wagner, J. L., O’Connor, D. M. A., Donsante, A., & Boulis, N. M. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00067 · Cited by 16
“Grimm et al. found the morbidity to be associated with downregulation of miRNAs derived from the liver, possibly indicating competition with the shRNAs (Grimm et al., 2006).”
BackgroundProspects of siRNA cocktails as tools for modifying multiple gene targets in the injured spinal cord
Michael, F. M., Chandran, P., Chandramohan, K., Iyer, K., Jayaraj, K. L., Revathidevi, S., & Venkatachalam, S. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219871868 · Cited by 14
“In addition, dysregulation of the innate functions of miRNAs due to nonavailability of RISC could lead to cytotoxicity.(42) Likewise, chemical modifications and/or conjugations can present additional problems of complexity in design, unpredictability of dissociation upon entry into the cells and retention of potency.”
BackgroundRNA Interference in Research and Therapy of Renal Diseases
cz, Z. R. A., & Hamar, P. (2008) · KARGER eBooks · doi:10.1159/000125587 · Cited by 14
Sano, M., Nakasu, A., Ohtaka, M., & Nakanishi, M. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.012 · Cited by 13
“However, shRNA gives rise to severe cytotoxicity through saturation of the endogenous miRNA pathway.(50) By contrast, amiRNAs were shown to be strong RNAi effectors, while significantly attenuating cytotoxicity and the immune response.”
Background
Metadata
- Authors
- Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Universitätsklinikum Aachen (DE)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 537-541
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1971643509
- Cited by
- 1,677
- References
- 31
- Citations by year
- 2026: 27 · 2025: 32 · 2024: 49 · 2023: 35 · 2022: 57 · 2021: 36 · 2020: 45 · 2019: 54 · 2018: 54 · 2017: 60 · 2016: 75 · 2015: 94 · 2014: 92 · 2013: 121 · 2012: 121
- FWCI
- 57.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- RNA interference, shRNA, microRNA, XPO5, hepatotoxicity, liver injury, AAV8 vector, siRNA delivery, karyopherins, post-transcriptional gene silencing, mice, gene silencing therapy, dose-dependent toxicity
- MeSH terms
- Animals, Hepatitis B virus, Humans, Liver, Liver Regeneration, Mice, Transgenic, Nucleic Acid Conformation, RNA, Survival Analysis, Karyopherins, RNA Interference, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.